Stratence Partners participates in the Andersen Consulting Global Partners Meeting in Las Vegas, represented by CEO Fernando Ventureira.

At EPA Amsterdam 2026, Fernando Ventureira, CEO of Stratence Partners, presented two sessions addressing critical challenges for pharmaceutical and MedTech companies: mastering Gross to Net complexity and embedding AI into commercial decision making. This article summarizes the key insights on how organizations can transform pricing, access, and commercial execution into a unified performance system.

A moment captured at EPA 2026 in Amsterdam reflects the importance of teamwork across Andersen and Stratence Partners leadership, bringing together expertise from Tax, Commercial Transformation and Healthcare industry strategy.

Life & Annuity carriers are facing record demand — but volume is masking structural inefficiencies. This paper explores how business-driven AI enables scalable, profitable growth beyond linear expansion models.

At EPA 2026, Stratence Partners will lead two executive sessions in the Pricing and AI tracks and host business-focused Poster Sessions on Commercial Transformation, AI Powered. Meet us at Booth 300A.

Fernando Ventureira will be in Amsterdam next week. Coffee or dinner with local business leaders.

Ahead of EPA 2026, Stratence Partners is hosting a closed-door VIP Dinner for selected VP and C-level executives in Pricing, Market Access, Commercial and Finance governance.

Animal Health companies face structural margin erosion from fragmented pricing, opaque gross-to-net dynamics, and misaligned execution. AI-Powered Commercial Transformation is no longer optional — it is strategic.

Commercial Transformation is not about isolated pricing initiatives. It is about structurally aligning strategy, pricing economics and commercial execution into one integrated, governed and AI Powered system that delivers sustainable competitive advantage.